Seshu Tyagarajan Sells 14,851 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 14,851 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $6.47, for a total value of $96,085.97. Following the completion of the transaction, the chief technology officer now owns 146,049 shares of the company’s stock, valued at $944,937.03. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Seshu Tyagarajan also recently made the following trade(s):

• On Thursday, July 11th, Seshu Tyagarajan sold 13,330 shares of Candel Therapeutics stock. The shares were sold at an average price of $5.97, for a total transaction of $79,580.10.

Candel Therapeutics Price Performance

Shares of Candel Therapeutics stock traded up $0.04 during trading on Friday, reaching $6.27. 15,302 shares of the stock traded hands, compared to its average volume of 2,756,216. The business has a fifty day simple moving average of $7.80 and a two-hundred day simple moving average of $4.66. Candel Therapeutics, Inc. has a 52-week low of $0.66 and a 52-week high of $14.30. The company has a market capitalization of $186.60 million, a price-to-earnings ratio of -4.90 and a beta of -0.95. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.00 and a quick ratio of 2.00.

Candel Therapeutics (NASDAQ:CADL) last announced its earnings results on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter. Sell-side analysts expect that Candel Therapeutics, Inc. will post -0.91 EPS for the current year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.